×
About 4,145 results

ALLMedicine™ Brain Metastasis Center

Research & Reviews  1,435 results

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT04791384

Jan 13th, 2022 - This is a multi-institutional, Phase Ib/II study in patients with HR+/Her2- breast cancer metastatic to the brain. Patients may have received up to two prior lines of systemic chemotherapy for locally advanced or metastatic disease. There will be ...

The role of brain metastases in patients with pulmonary adenocarcinoma: a retrospective...
https://doi.org/10.21037/apm-21-3146
Annals of Palliative Medicine; Xue J, Liu M et. al.

Jan 13th, 2022 - Brain metastasis is common in patients with lung cancer and has a negative impact on overall survival (OS). The aim of this study was to investigate therapeutic effects and prognosis-related factors for survival of patients with pulmonary adenocar...

Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (...
https://doi.org/10.1007/s11060-021-03893-6
Journal of Neuro-oncology; Peña Pino I, Ma J et. al.

Jan 11th, 2022 - The optimal treatment paradigm for brain metastasis that recurs locally after initial radiosurgery remains an area of active investigation. Here, we report outcomes for patients with BMRS treated with stereotactic laser ablation (SLA, also known a...

Transcription Factors Leading to High Expression of Neuropeptide L1CAM in Brain Metasta...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739529
Disease Markers; Feng X, Guan N et. al.

Jan 11th, 2022 - There is a lack of understanding of the development of metastasis in lung adenocarcinoma (LUAD). This study is aimed at exploring the upstream regulatory transcription factors of L1 cell adhesion molecule (L1CAM) and to construct a prognostic mode...

Changing characteristics, treatment approaches and survival of patients with brain meta...
https://doi.org/10.1016/j.ejca.2021.12.005
European Journal of Cancer (Oxford, England : 1990); Steindl A, Brunner TJ et. al.

Jan 9th, 2022 - An accurate classification of patients with brain metastases (BMs) is an important foundation to guide individualised treatment decisions and to formulate BM cohorts for modern clinical trials. Six thousand and thirty-one patients with newly diagn...

see more →

Guidelines  2 results

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patien...
https://doi.org/10.1016/j.annonc.2021.07.016
Annals of Oncology : Official Journal of the European Soc... Le Rhun E, Guckenberger M et. al.

Aug 9th, 2021 - EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.|2021|Le Rhun E,Guckenberger M,Smits M,Dummer R,Bachelot T,|diagnosis,therapy,

A Cancer Care Ontario Organizational Guideline for the Delivery of Stereotactic Radiosu...
https://doi.org/10.1016/j.prro.2019.11.002
Practical Radiation Oncology; Sahgal A, Kellett S et. al.

Nov 30th, 2019 - In Ontario, Canada, there is increasing demand for stereotactic radiosurgery (SRS) for brain metastases. Recommendations for safe SRS delivery are needed to ensure that patients receive an equitable level of care across the province. This guidelin...

see more →

Clinicaltrials.gov  86 results

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT04791384

Jan 13th, 2022 - This is a multi-institutional, Phase Ib/II study in patients with HR+/Her2- breast cancer metastatic to the brain. Patients may have received up to two prior lines of systemic chemotherapy for locally advanced or metastatic disease. There will be ...

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis
https://clinicaltrials.gov/ct2/show/NCT05180422

Jan 6th, 2022 - Each patient is scheduled to receive AMG 510 (KRASG12C inhibitor) in combination with MVASI (vascular endothelial growth factor [VEGF] inhibitor; bevacizumab biosimilar); both drugs will be provided by the study: AMG 510: Continuous once daily (QD...

Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
https://clinicaltrials.gov/ct2/show/NCT02993146

Jan 5th, 2022 - PRIMARY OBJECTIVE: I. To conduct a phase 1 dose escalation trial in patients with brain metastases to determine the recommended phase -2 dose of ropidoxuridine (5-iodo-2-pyrimidinone-2'-deoxyribose [IPdR]) when administered alone orally once daily...

Seizure Prophylaxis Study
https://clinicaltrials.gov/ct2/show/NCT03436433

Dec 30th, 2021 - The protocol will assess the need for AED prophylaxis during the post-operative period in patients undergoing neurosurgical procedure for a suspected diagnosis of glioma (WHO grade I-IV) and brain metastasis. Patients (n=116) will be consented and...

Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma
https://clinicaltrials.gov/ct2/show/NCT05173610

Dec 30th, 2021 - Oligometastasis is a definition that has been described in the past in the 1990s, and in some patients, metastases are not extensive and are limited to a small number of metastases. The local ablative treatment for oligometastasis is not a new con...

see more →

News  135 results

New Indication Propels Brigatinib Into the Front Line for ALK-Positive NSCLC
https://www.onclive.com/view/new-indication-propels-brigatinib-into-the-front-line-for-alk-positive-nsclc

Jan 3rd, 2022 - The tyrosine kinase inhibitor brigatinib (Alunbrig) holds the promise of superior outcomes compared with standard-of-care option crizotinib (Xalkori) in patients with ALK-mutant non–small cell lung cancer (NSCLC). On May 22, 2020, the FDA approved...

Treatment of Advanced NSCLC With Dual Immune Checkpoint Inhibitors: 4-Year Update of CheckMate 227
https://www.onclive.com/view/treatment-of-advanced-nsclc-with-dual-immune-checkpoint-inhibitors-4-year-update-of-checkmate-227

Nov 16th, 2021 - John V. Heymach, MD, PhD: Sandip, 1 thing that’s different from the drugs we’re talking about is the combination of PD-1 and CTLA4. We’ve got the CheckMate 227 study. We saw the update. Do you want to take us through that? There’s also a group tha...

Recent Updates in EGFR-Mutant NSCLC Treatment Landscape
https://www.onclive.com/view/recent-updates-in-egfr-mutant-nsclc-treatment-landscape

Nov 16th, 2021 - John V. Heymach, MD, PhD: We have some new studies coming out at the ESMO [European Society for Medical Oncology] 2021 Meeting and other meetings here. We had a study of bevacizumab [Avastin] and erlotinib [Tarceva], the BEVERLY study. Vamsi, what...

Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm
https://www.onclive.com/view/immunotherapy-chemo-combos-remain-go-to-option-in-growing-small-cell-lung-cancer-paradigm

Nov 6th, 2021 - Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer (SCLC), explained Taofeek K. Owonikoko, MD, PhD, adding that other novel agents, such as, bispecific T-cell engagers (BiTEs) are in the pipeline and ...

NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations
https://www.onclive.com/view/nsclc-future-treatment-landscape-of-egfr-exon-20-insertion-mutations

Nov 4th, 2021 - Transcript: Catherine Ann Shu, MD: All of your patients need to have comprehensive genetic testing on their tumors. That’s the most important thing I can say. It’s important not only for EGFR exon 20 mutations, but also important for all the othe...

see more →